biomedical research

Lawmakers Call for Probes into Planned Parenthood Video Allegations

REUTERS / Dominick Reuter / RNS
The Planned Parenthood logo is pictured outside a clinic in Boston, Massachusetts, on June 27, 2014. Photo via REUTERS / Dominick Reuter / RNS

Lawmakers are calling for investigations into a health care provider that has come under fire by anti-abortion activists for allegedly selling fetal organs for profit.

The anti-abortion group Center for Medical Progress claims that the Planned Parenthood foundation violated the law by selling the fetal tissue to medical researchers.

Planned Parenthood spokesman Eric Ferrero vehemently denied the accusations, saying that the tissue in question was donated to medical research – not sold.

“These outrageous claims are flat-out untrue, but that doesn’t matter to politicians with a longstanding political agenda to ban abortion and defund Planned Parenthood,” Ferrero said.

We Paid for Them

IN THE LATE 1980s, while fear and prejudice stymied global progress against the AIDS pandemic, the National Institutes of Health (NIH) launched a publicly funded program to translate basic HIV research into lifesaving medicines.

One grant went to a team led by John Erickson at Abbott Laboratories, where, in his words, it “catalyzed the development of [Abbott’s] antiviral program” at a time when such efforts “were largely nonexistent in the pharmaceutical industry.” The government money “facilitated the research that led directly to the development” of ritonavir—one of the most important HIV medicines to date. Ritonavir, taken in combination with other HIV medicines, makes them more effective. It’s a key treatment for people who have developed resistance to first-line drugs.

In many countries Abbott patented ritonavir and numerous variations; one of Abbott’s patents for a combination product will not expire until 2026. Despite the public’s investment, Abbott aggressively asserts a high-priced monopoly around the world, charging many times what generics would cost. (In some of the few countries where ritonavir combinations are not patented—through Abbott’s inaction or the government’s refusal—a combination drug runs only about $450 per year.)

The biggest problem: Abbott’s patents and prices prevent economies of scale in generic drug production and donor purchasing, restricting the world’s ability to improve HIV treatment and prevention in countries from Vietnam to Colombia. What’s more, Abbott’s behavior discourages development of lifesaving combination therapies that bundle the drug with non-Abbott HIV medicines.

Read the Full Article

​You've reached the end of our free magazine preview. For full digital access to Sojourners articles for as little as $2.95, please subscribe now. Your subscription allows us to pay authors fairly for their terrific work!
Subscribe Now!

Subscribe